Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04285671 · ClinicalTrials.gov registry record · Phase 1

Necitumumab and Trastuzumab in Combination With Osimertinib for the Treatment of Refractory Epidermal Growth Factor Receptor (EGFR)-Mutated Stage IV Non-small Cell Lung Cancer

A Phase 1 study of Metastatic Lung Non-Small Cell Carcinoma and Stage IVA Lung Cancer AJCC v8, sponsored by Jonsson Comprehensive Cancer Center.

Active
Registry status
Phase 1
Development phase
30
Enrollment target
1
Study location

NCT04285671: Active Phase 1 study of Metastatic Lung Non-Small Cell Carcinoma and Stage IVA Lung Cancer AJCC v8, sponsored by Jonsson Comprehensive Cancer Center.

NCT04285671 is a Phase 1 study of Metastatic Lung Non-Small Cell Carcinoma and Stage IVA Lung Cancer AJCC v8 that is active but no longer recruiting, run by Jonsson Comprehensive Cancer Center. The registered enrollment target is 30 participants, below the 77-participant average among 39 other Metastatic Lung Non-Small Cell Carcinoma trials with a reported enrollment target (61% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04285671, a Phase 1 study of Metastatic Lung Non-Small Cell Carcinoma and Stage IVA Lung Cancer AJCC v8, is active but no longer recruiting, sponsored by Jonsson Comprehensive Cancer Center.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
30 participants
Enrollment target
1
Study location

Study Summary

This phase Ib/II trial studies the side effects and best dose of trastuzumab and necitumumab together with osimertinib, and to see how well they work for the treatment of stage IV non-small cell lung cancer that is EGFR-mutated, resistant to osimertinib, and has not responded to previous treatment (refractory). Immunotherapy with monoclonal antibodies, such as trastuzumab and necitumumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Osimertinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving trastuzumab and necitumumab together with osimertinib may work better than osimertinib alone in treating patients with stage IV EGFR-mutated non-small cell lung cancer.

Conditions Studied

Metastatic Lung Non-Small Cell Carcinoma Stage IVA Lung Cancer AJCC v8 Stage IVB Lung Cancer AJCC v8 Refractory Lung Non-Small Cell Carcinoma Stage IV Lung Cancer American Joint Committee on Cancer (AJCC) v8

Interventions

  • OTHER Quality-of-Life Assessment
  • DRUG Osimertinib
  • OTHER Questionnaire Administration
  • BIOLOGICAL Trastuzumab
  • BIOLOGICAL Necitumumab

Study Locations (1)

California

  • UCLA / Jonsson Comprehensive Cancer Center - Los Angeles

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2021-01-29
Est. Completion 2027-12-02
Phase Phase 1
Jonsson Comprehensive Cancer Center

321 total trials

What the registry record for NCT04285671 still lists

NCT04285671 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 77-participant average among 39 other Metastatic Lung Non-Small Cell Carcinoma trials with a reported enrollment target (61% lower).

The record links to 5 conditions, with Metastatic Lung Non-Small Cell Carcinoma appearing as the primary indexed condition, and to 5 interventions - of which Quality-of-Life Assessment is the first listed.

NCT04285671 reports a single indexed study location in California.

Frequently Asked Questions

What is clinical trial NCT04285671 about?

NCT04285671 is a clinical study titled "Necitumumab and Trastuzumab in Combination With Osimertinib for the Treatment of Refractory Epidermal Growth Factor Receptor (EGFR)-Mutated Stage IV Non-small Cell Lung Cancer". This phase Ib/II trial studies the side effects and best dose of trastuzumab and necitumumab together with osimertinib, and to see how well they work for the treatment of stage IV non-small cell lung cancer that is EGFR-mutated, resistant to osimertinib, and has not responded to previous treatment (...

What is the current status of trial NCT04285671?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2021-01-29. Estimated completion is 2027-12-02.

What conditions does trial NCT04285671 study?

This clinical trial studies the following conditions: Metastatic Lung Non-Small Cell Carcinoma, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8, Refractory Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer American Joint Committee on Cancer (AJCC) v8.

What interventions are being tested in trial NCT04285671?

The interventions under investigation include: Quality-of-Life Assessment (OTHER), Osimertinib (DRUG), Questionnaire Administration (OTHER), Trastuzumab (BIOLOGICAL), Necitumumab (BIOLOGICAL).

Who is sponsoring clinical trial NCT04285671?

This trial is sponsored by Jonsson Comprehensive Cancer Center, which has 321 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04285671 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Metastatic Lung Non-Small Cell Carcinoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT04285671's enrollment target sits among peer trials

30 23rd of 39 higher than 15 of 39 other Metastatic Lung Non-Small Cell Carcinoma trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Metastatic Lung Non-Small Cell Carcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00977977 · 30 participants · Phase 2

    Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy

  • NCT01459107 · 30 participants · Phase 2

    Human Upper Extremity Allotransplantation

  • NCT01666080 · 30 participants · NA

    Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)

  • NCT01720836 · 30 participants · Phase 1

    Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT04285671, the US trial registry maintained by the National Library of Medicine. NCT04285671 (small enrollment · single site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.